US Patent

US11311488 — Osmotic dosage forms comprising deutetrabenazine and methods of use thereof

Method of Use · Assigned to Auspex Pharmaceuticals Inc · Expires 2041-06-10 · 15y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects osmotic dosage forms containing deutetrabenazine for use in treating hyperkinetic movement disorders.

USPTO Abstract

Provided herein are osmotic dosage forms containing deutetrabenazine for use in the treatment of, e.g., hyperkinetic movement disorders. When orally administered to a subject on a once-daily basis, the dosage forms provide a favorable pharmacokinetic profile for the active agent indicating treatment efficacy over an extended period of time.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-1995 — Austedo
U-1995 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo
U-3055 — Austedo

Patent Metadata

Patent number
US11311488
Jurisdiction
US
Classification
Method of Use
Expires
2041-06-10
Drug substance claim
No
Drug product claim
Yes
Assignee
Auspex Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.